Extrait

The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

Critère d'inclusion

• Renal Cell Carcinoma

Pays

• Canada
• Finland
• Italy
• United States

Liens

• euctr
• ictrp
• ictrp
• euctr
• nct
• ictrp